Analysts Expect Avanos Medical Inc (AVNS) Will Announce Quarterly Sales of $165.67 Million
Wall Street analysts predict that Avanos Medical Inc (NYSE:AVNS) will post sales of $165.67 million for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Avanos Medical’s earnings, with the lowest sales estimate coming in at $163.10 million and the highest estimate coming in at $168.60 million. Avanos Medical posted sales of $166.30 million in the same quarter last year, which would indicate a negative year-over-year growth rate of 0.4%. The firm is scheduled to issue its next earnings results before the market opens on Tuesday, February 26th.
On average, analysts expect that Avanos Medical will report full year sales of $647.95 million for the current year, with estimates ranging from $645.50 million to $651.00 million. For the next year, analysts forecast that the company will report sales of $690.17 million, with estimates ranging from $688.60 million to $691.60 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Avanos Medical.
A number of equities analysts have commented on the stock. Zacks Investment Research cut shares of Avanos Medical from a “hold” rating to a “sell” rating in a research report on Wednesday, November 7th. TheStreet cut shares of Avanos Medical from a “b-” rating to a “c” rating in a research report on Wednesday, November 7th. KeyCorp reduced their price objective on shares of Avanos Medical from $68.00 to $67.00 and set an “overweight” rating for the company in a research report on Tuesday, December 18th. Finally, Barclays cut shares of Avanos Medical from an “equal weight” rating to an “underweight” rating in a research report on Friday, January 4th. Two analysts have rated the stock with a sell rating, one has given a hold rating and two have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $67.25.
In other Avanos Medical news, CEO Joseph Fralin Woody bought 3,500 shares of Avanos Medical stock in a transaction dated Wednesday, November 28th. The stock was bought at an average price of $43.35 per share, with a total value of $151,725.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Steven E. Voskuil bought 2,000 shares of Avanos Medical stock in a transaction dated Tuesday, November 27th. The stock was acquired at an average cost of $43.74 per share, with a total value of $87,480.00. The disclosure for this purchase can be found here. Insiders own 1.44% of the company’s stock.
Institutional investors have recently made changes to their positions in the company. First Hawaiian Bank bought a new stake in shares of Avanos Medical in the fourth quarter valued at about $45,000. Bollard Group LLC bought a new stake in shares of Avanos Medical in the third quarter valued at about $100,000. Rehmann Capital Advisory Group bought a new stake in shares of Avanos Medical in the third quarter valued at about $108,000. Whittier Trust Co. bought a new stake in shares of Avanos Medical in the third quarter valued at about $110,000. Finally, Public Employees Retirement System of Ohio bought a new stake in shares of Avanos Medical in the second quarter valued at about $136,000. 91.08% of the stock is owned by institutional investors.
Avanos Medical Company Profile
Avanos Medical, Inc operates as a medical technology company that focuses on eliminating pain, speeding recovery, and preventing infection for healthcare providers and patients worldwide. Its Medical Devices segment provides a portfolio of products that focuses on respiratory and digestive health, along with surgical and interventional pain management.
Further Reading: Asset Allocation, Balancing Your Investments
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Avanos Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avanos Medical and related companies with MarketBeat.com's FREE daily email newsletter.